Earnings summaries and quarterly performance for CVRx.
Executive leadership at CVRx.
Kevin Hykes
Detailed
President and Chief Executive Officer
CEO
BB
Brent Binkowski
Detailed
Chief Operating Officer
JO
Jared Oasheim
Detailed
Chief Financial Officer
PV
Paul Verrastro
Detailed
Chief Marketing and Strategy Officer
PA
Philip Adamson
Detailed
Chief Medical Officer
RJ
Robert John
Detailed
Chief Revenue Officer
Board of directors at CVRx.
Research analysts who have asked questions during CVRx earnings calls.
Chase Knickerbocker
Craig-Hallum Capital Group
6 questions for CVRX
Also covers: AVDL, BFLY, BVS +17 more
Frank Takkinen
Lake Street Capital Markets
5 questions for CVRX
Also covers: ANGO, AORT, AXGN +17 more
MK
Macauley Kilbane
William Blair & Company
5 questions for CVRX
Also covers: CBLL, GKOS, IRTC +4 more
RP
Rohin Patel
JPMorgan Chase & Co.
5 questions for CVRX
Also covers: HAE, INGN, NPCE
RO
Ross Osborn
Cantor Fitzgerald
4 questions for CVRX
Also covers: AXGN, CERS, ELUT +12 more
SM
Samantha Munoz
Piper Sandler Companies
3 questions for CVRX
Also covers: ATEC, PEN, TELA +1 more
William Plovanic
Canaccord Genuity
2 questions for CVRX
Also covers: ATRC, CBLL, DXCM +9 more
BV
Brandon Vazquez
William Blair & Company, L.L.C.
1 question for CVRX
Also covers: ALGN, CBLL, DXCM +16 more
JY
John Young
Canaccord Genuity - Global Capital Markets
1 question for CVRX
Also covers: ANGO, IRTC, LUNG +2 more
Nelson Cox
Lake Street Capital Markets
1 question for CVRX
Also covers: AORT, AQST, IRMD +6 more
S
Samantha
Piper Sandler & Co.
1 question for CVRX
Also covers: RCEL, SIBN
Recent press releases and 8-K filings for CVRX.
CVRx Reports 2025 Financial Results, Provides 2026 Guidance, and Details Strategic Initiatives
CVRX
Guidance Update
New Projects/Investments
Debt Issuance
- CVRx reported its preliminary financial results for Q4 2025 and full-year 2025, and provided guidance for full-year 2026 : | Metric | Q4 2025 | FY 2025 | FY 2026 (Guidance) | |---|---|---|---| | Worldwide Revenue ($USD Millions) | $15.9 - $16.1 | $56.5 - $56.7 | $63 - $67 | | Revenue Growth Rate (%) | N/A | 11% | N/A | | Gross Margin (%) | N/A | N/A | 84% - 86% | | Operating Expenses ($USD Millions) | N/A | N/A | $103 - $107 |
- The company's cash balance was $75.7 million at the end of 2025, which increased to $86 million in early January 2026 after drawing an additional $10 million from an amended $100 million debt facility with Innovatus, extending its maturity to 2031.
- CVRx received FDA IDE approval for the BENEFIT-HF trial, a landmark study designed to expand its market opportunity from $10 billion to over $30 billion. This trial, with an estimated net cost of $20 million to $30 million over five to seven years, is anticipated to begin enrollment later in 2026.
- The implementation of Category I CPT codes on January 1, 2026, is expected to significantly reduce reimbursement friction and improve physician confidence, supported by 30-day Medicare Advantage approval rates that finished 2025 at 46%, up from 31% in 2024.
21 hours ago
CVRx Reports 2025 Financials and 2026 Outlook, Details Strategic Growth Initiatives
CVRX
Guidance Update
Debt Issuance
New Projects/Investments
- CVRx reported Q4 2025 worldwide revenue of $15.9-$16.1 million and full-year 2025 worldwide revenue of $56.5-$56.7 million, representing 11% growth. The company provided 2026 full-year revenue guidance of $63-$67 million and Q1 2026 revenue guidance of $13.7-$14.7 million.
- The company announced the implementation of Category 1 CPT codes on January 1, 2026, which is expected to significantly reduce reimbursement friction and formalize physician payment. 30-day Medicare Advantage approval rates for 2025 reached 46%, up from 31% in 2024.
- CVRx received FDA IDE approval for the BenefitHF trial, a landmark randomized controlled trial designed to expand its indication. If successful, this trial is projected to triple the total addressable market (TAM) from $10 billion to over $30 billion.
- The company's cash balance at the end of 2025 was $75.7 million, increasing to $86 million in early January 2026 after drawing an additional $10 million from an amended $100 million loan facility. Cash burn for 2025 was in the range of $35-$40 million, with expectations for a reduced burn in 2026.
21 hours ago
CVRx Updates 2025 Financials and Provides 2026 Guidance, Announces Market Expansion Trial, and Amends Debt Facility
CVRX
Guidance Update
New Projects/Investments
Debt Issuance
- CVRx reported preliminary Q4 2025 worldwide revenue of $15.9-$16.1 million and FY 2025 worldwide revenue of $56.5-$56.7 million, representing an 11% growth rate. The company provided FY 2026 worldwide revenue guidance of $63-$67 million and Q1 2026 revenue guidance of $13.7-$14.7 million.
- The company implemented Category 1 CPT codes on January 1, 2026, which formalizes physician payment and removes the ability for payers to automatically deny prior authorizations for its Barostim therapy, with inpatient reimbursement at $45,000 and outpatient payment at $43,000.
- CVRx received FDA IDE approval for the BenefitHF trial, which aims to expand the Barostim indication and could triple the total addressable market from $10 billion to over $30 billion. Enrollment for this 2,500-patient trial is expected to begin later in 2026 and continue through 2030.
- The loan agreement with Innovatus was amended, extending the $50 million facility to $100 million with a new maturity date of 2031, and an additional $10 million was drawn on January 9th, 2026, increasing the cash balance to $86 million.
22 hours ago
CVRX provides preliminary 2025 results and 2026 guidance, highlights market opportunity and strategic progress
CVRX
Earnings
Guidance Update
New Projects/Investments
- CVRX reported preliminary worldwide revenue of $56.5-$56.7 million for full year 2025 and provided 2026 revenue guidance between $63.0 million and $67.0 million.
- The company expects gross margin for FY 2025 to be 85%-86% and for FY 2026 to be between 84% and 86%.
- CVRX estimates a $10.5 billion prevalence-based market opportunity for Barostim in the U.S. HFrEF market, with potential expansion to approximately 983,000 patients if the BENEFIT-HF randomized controlled trial is successful.
- Patient access has improved with the activation of new Category I codes as of January 1st, eliminating automatic Category III denials and establishing consistent surgeon payment.
- The company received IDE approval for BENEFIT-HF, a landmark randomized controlled trial for heart failure, with enrollment expected from 1H 2026 to 2030, potentially expanding the market opportunity.
1 day ago
CVRx Faces Investor Investigation
CVRX
Legal Proceedings
Profit Warning
Management Change
- Wolf Popper LLP is investigating potential claims on behalf of purchasers of CVRx, Inc. common stock.
- The investigation stems from CVRx's announcement of weak Q1 2024 results, which the company attributed to salesforce disruption following the prior Chief Executive Officer's retirement.
- Despite management's subsequent assurances of a stabilized salesforce, CVRx announced weak preliminary Q1 2025 results on April 7, 2025, causing its stock price to fall $5.34 per share (46.3%) on April 8, 2025.
- Following this, CVRx announced weak Q1 2025 results and lowered its full-year revenue guidance on May 8, 2025, leading to an additional $3.01 per share (38.7%) stock price decline on May 9, 2025.
- The CEO acknowledged that the depth of salesforce changes was more significant than anticipated, with 25% of current territory managers hired between December and March, impacting productivity.
2 days ago
CVRx, Inc. enters into $50 million at-the-market equity offering agreement
CVRX
- CVRx, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on January 12, 2026.
- This agreement allows CVRx, Inc. to offer and sell up to $50.0 million of its common stock through an "at-the-market offering".
- Jefferies LLC will act as the sales agent and receive a commission of up to 3.0% of the gross proceeds from the sale of shares.
- The net proceeds from the offering are intended for working capital and general corporate purposes.
3 days ago
CVRx Reports Preliminary Q4 and FY 2025 Results, Issues 2026 Guidance, and Amends Debt Facility
CVRX
Earnings
Guidance Update
Debt Issuance
- CVRx reported preliminary fourth quarter 2025 revenue between $15.9 million and $16.1 million, and full year 2025 revenue between $56.5 million and $56.7 million.
- The company issued fiscal year 2026 revenue guidance of $63.0 million to $67.0 million, and first quarter 2026 revenue guidance of $13.7 million to $14.7 million.
- CVRx amended its debt facility on January 9, 2026, increasing the available term loans by $50 million to an aggregate of up to $100 million, extending the maturity date to May 9, 2031, and drawing an additional $10 million for a total outstanding principal of $60 million.
- As of December 31, 2025, cash and cash equivalents were $75.7 million.
- The FDA approved the BENEFIT-HF trial design in November 2025, which could expand the U.S. market opportunity from $10.5 billion to $30.5 billion if successful and approved by CMS.
3 days ago
CVRx Reports Preliminary Q4 and Full Year 2025 Results and Issues 2026 Guidance
CVRX
Earnings
Guidance Update
Debt Issuance
- CVRx expects preliminary fourth quarter 2025 revenue to be between $15.9 million and $16.1 million, and full year 2025 revenue between $56.5 million and $56.7 million.
- For fiscal year 2026, the company anticipates total revenue between $63 million and $67 million, with gross margin between 84% and 86%, and operating expenses between $103.0 million and $107.0 million.
- As of December 31, 2025, CVRx had cash and cash equivalents of $75.7 million.
- The debt facility was amended on January 9, 2026, increasing the facility by $50 million to an aggregate of up to $100 million, with $10 million funded at closing, bringing the total outstanding principal to $60 million and extending the maturity to May 2031.
- Category I CPT codes and related favorable physician fee payment levels took effect on January 1, 2026, which is expected to remove key adoption barriers and support commercial efforts.
3 days ago
CVRx Discusses Sales Force Productivity, New Clinical Trial, and Reimbursement Updates
CVRX
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- CVRx is undergoing a sales force transformation, with 50 active territories and plans to add approximately three per quarter, targeting $1.8 million in annual revenue per rep.
- The company has agreed with the FDA on a design for a new 2,500-patient Randomized Controlled Trial (RCT) to expand its indication, which is projected to triple its Total Addressable Market (TAM). This trial is estimated to cost $20 million-$30 million over four to six years.
- Reimbursement updates include permanent inpatient and outpatient coverage at $45,000 , and a new Category I code effective in about three weeks that will provide specific surgeon payment and streamline prior authorizations.
- CVRx reported a Q3 gross margin of 87% with an average selling price (ASP) of $32,000. The company holds $85 million in cash and expects at least three years of cash on the balance sheet, with the RCT's cash burn primarily in later years.
Dec 3, 2025, 7:00 PM
CVRx Discusses Q4 Outlook, Sales Force Strategy, New Clinical Trial, and Financials
CVRX
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- CVRx anticipates a conservative Q4 with approximately $1 million of incremental revenue sequentially, following a Q1 sales force transformation. The company currently has 50 active territories and plans to add about three per quarter.
- The target for sales reps is $1.8 million in annual revenue per territory, up from a historical $1 million, which is crucial for achieving cash flow break-even.
- CVRx is proceeding with a new randomized controlled trial (RCT) of 2,500 patients to expand its indication, aiming to triple its Total Addressable Market (TAM). The trial is estimated to cost $20 million-$30 million over four to six years for enrollment and follow-up, with the majority of cash burn expected in later years.
- Q3 gross margin reached 87%, driven by an average selling price (ASP) of $32,000 and cost efficiencies, with future gross margins expected in the 85%-86% range.
- CVRx holds $85 million in cash and projects at least three years of cash on hand, assuming debt refinancing. Recent reimbursement successes include securing permanent inpatient reimbursement of $45,000 and an upcoming Category I code to streamline surgeon payments and prior authorizations.
Dec 3, 2025, 7:00 PM
Quarterly earnings call transcripts for CVRx.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more